A strong humoral immune response induced by a vaccine formulation containing rSm29 adsorbed to alum is associated with protection against schistosoma mansoni reinfection in mice

Página do item simplificado
dc.creatorClarice Carvalho Alves
dc.creatorNeusa Araujo
dc.creatorWilma Patrícia de Oliveira Santos Bernardes
dc.creatorMariana Moreira Mendes
dc.creatorSergio Costa Oliveira
dc.creatorCristina Toscano Fonseca
dc.date.accessioned2024-09-19T19:55:58Z
dc.date.accessioned2025-09-08T23:13:20Z
dc.date.available2024-09-19T19:55:58Z
dc.date.issued2018
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.mimetypepdf
dc.identifier.doi10.3389/fimmu.2018.02488
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/1843/76708
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofFrontiers in Immunology
dc.rightsAcesso Aberto
dc.subjectSchistosoma mansoni
dc.subjectEsquistossomose
dc.subjectVacinas
dc.subject.otherSchistosoma mansoni
dc.subject.otherrSM29
dc.subject.othermice
dc.titleA strong humoral immune response induced by a vaccine formulation containing rSm29 adsorbed to alum is associated with protection against schistosoma mansoni reinfection in mice
dc.typeArtigo de periódico
local.citation.epage12
local.citation.spage1
local.citation.volume9
local.description.resumoThe helminth Schistosoma mansoni is one of main causes of human schistosomiasis, a health and economic concern in some of the world's poorest countries. Current treatment regimens can lead to serious side effects and are not suitable for breastfeeding mothers. As such, efforts have been undertaken to develop a vaccine to prevent infection. Of these, Sm29 is a promising candidate that has been associated with resistance to infection/reinfection in humans and mice. Its ability to induce resistance to reinfection has also been recently demonstrated using a vaccine formulation containing Freund's adjuvant. However, Freund's adjuvant is unsuitable for use in human vaccines. We therefore evaluated the ability of Sm29 to induce protection against S. mansoni reinfection when formulated with either alum or MPLA as an adjuvant, both approved for human use. Our data demonstrate that, in contrast to Sm29 with MPLA, Sm29 with alum reduced parasite burden after reinfection compared to a control. We next investigated whether the immune response was involved in creating the differences between the protective (Sm29Alum) and non-protective (Sm29MPLA) vaccine formulations. We observed that both formulations induced a similar mixed-profile immune response, however, the Sm29 with alum formulation raised the levels of antibodies against Sm29. This suggests that there is an association between a reduction in worm burden and parasite-specific antibodies. In summary, our data show that Sm29 with an alum adjuvant can successfully protect against S. mansoni reinfection in mice, indicating a potentially effective vaccine formulation that could be applied in humans.
local.publisher.countryBrasil
local.publisher.departmentICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02488/full

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against Schistosoma mansoni Reinfection in Mice.pdf
Tamanho:
2.05 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG